Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).
暂无分享,去创建一个
C Sebban | B. Coiffier | H. Tilly | C. Gisselbrecht | C. Sebban | É. Lepage | C. Haioun | F. Reyes | P. Morel | R. Herbrecht | H Tilly | P Morel | R Herbrecht | C Haioun | C Gisselbrecht | F Reyes | E Lepage | A Bosly | B Coiffier | A. Bosly | P. Morel
[1] R. Fisher,et al. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] J. Radford,et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. , 1992, Blood.
[3] P. Duffey,et al. The calculation of actual or received dose intensity: a comparison of published methods. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] D. Neuberg,et al. Making cocktails versus making soup. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Armitage,et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] W. Hryniuk,et al. The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Connors,et al. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Fisher,et al. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] W. Hryniuk,et al. The calculation of received dose intensity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R A Olshen,et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] B. Coiffier,et al. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] S M Hubbard,et al. The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture. , 1987, Cancer research.
[13] A. Dembo. Time-dose factors in chemotherapy: expanding the concept of dose-intensity. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] G. Pinkus,et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. , 1986, Annals of internal medicine.
[15] D. Weisenburger,et al. Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] W. Hryniuk,et al. The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Cox. Regression Models and Life-Tables , 1972 .
[18] M Tubiana,et al. Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.
[19] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .